Navigation Links
Longer Antiviral Therapy Reduces Lung Transplant Complications

Study finds 12-month course of valganciclover wards off dangerous CMV infections

MONDAY, June 14 (HealthDay News) -- Extended antiviral treatment after a lung transplant may help prevent dangerous complications and organ rejection, a new study from Duke University Medical Center shows.

A common cause of infection in lung transplant recipients is cytomegalovirus (CMV), which often causes mild effects but can be life-threatening for transplant patients. Standard preventive therapy involves taking the drug valganciclovir (Valcyte) for up to three months. But even with this treatment, most lung transplant patients develop CMV infections within a year.

The Duke study included 136 patients who completed three months of oral valganciclovir and then received either an additional nine months of placebo (66 patients) or an additional nine months of oral valganciclovir (70 patients). Since it was a double-blind, placebo-controlled randomized study, researchers compared two groups of randomly selected patients at 11 different centers (one group of which received the additional medication and a control group that received the placebo, with neither the researchers nor the participants knowing who was in the control group).

Researchers found that CMV infection occurred in 10 percent of the extended treatment group, compared to 64 percent of the placebo group. Pneumonia caused by CMV virus occurred in 4 percent of the extended-treatment group and in 32 percent of the placebo group.

"We found that 12 months of oral valganciclovir was extremely effective and led to a dramatic reduction in the rate of CMV infection and disease," Dr. Scott Palmer, scientific director of the Lung Transplant Program at Duke University Medical Center, said in a university news release.

Potential side effects of valganciclovir include nausea, diarrhea, anemia and other blood disorders, retinal detachment, headache, fever, vomiting, mental changes and other problems. However, the study "showed that there was no increased or added toxicity with the extended course of treatment," Palmer said.

"In addition, the study examined viral resistance mutations and demonstrated that extended therapy did not lead to increased drug resistance, a potential concern with longer courses of treatment," Palmer added.

The study, published in the June 15 issue of the Annals of Internal Medicine, was funded by Roche Pharmaceuticals, which makes Valcyte.

More information

The American Academy of Family Physicians has more about CMV.

-- Robert Preidt

SOURCE: Duke Medicine, June 14, 2010. news release.

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Using Nicotine Patch Longer Boosts Efforts to Quit
2. Sedation Linked to Longer Stay in ICU
3. Zambian study finds longer breastfeeding best for HIV-infected mothers
4. Pet Health Insurance Grows as Pets Live Longer and Healthier Lives
5. Marijuana Use No Longer Dropping Among U.S. Teens
6. Looking Younger Than Your Age May Mean Longer Life
7. Military children face more emotional challenges as parental deployments grow longer, study finds
8. Glaucoma Drugs May Play Role in Longer Life
9. Biological clock could be a key to better health, longer life
10. Big Smiles, Longer Lives?
11. Perhaps a longer lifespan, certainly a longer health span
Post Your Comments:
Related Image:
Longer Antiviral Therapy Reduces Lung Transplant Complications
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s ... the world, and the most handsome men, look naturally attractive. Plastic surgery should ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: